Enzyme immunoassay for the quantitative determination of free Pembrolizumab (Keytruda®) in serum and plasma.
This kit has been especially developed for the quantitative determination of pembrolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Pembrolizumab Drug Bank Accession Number is DB09037.
Pembrolizumab is a PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. As a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors, pembrolizumab binds with high affinity to the cell surface receptor programmed cell death protein 1 (PD-1) and antagonizes its interaction with its known ligands PD-L1 and PD-L2. The binding of pembrolizumab to PD-1 prevents this inhibitory pathway, causing a physiological shift towards immune reactivity and enhancing tumor immunosurveillance and anti-tumor immune response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact firstname.lastname@example.org
|Required Volume (µl)||10|
|Total Time (min)||140|
|Detection Limit (ng/mL)||10|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|